Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore W Laetsch

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 13, 2024
Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinibTheodore W Laetsch
The Lancet. Haematology|October 22, 2020
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?Theodore W Laetsch
The Lancet. Oncology|January 8, 2020
Immunoglobulin replacement and quality of life after CAR T-cell therapy - Authors' replyTheodore W Laetsch, Andrew C Harris
Expert Review of Anticancer Therapy|September 13, 2022
Targeting the DNA damage response in pediatric malignanciesJenna M Gedminas, Theodore W Laetsch
Expert Review of Anticancer Therapy|October 24, 2018
Larotrectinib for the treatment of TRK fusion solid tumorsTheodore W Laetsch, Douglas S Hawkins
Cancer Genetics|February 2, 2022
The promise of TRK inhibitors in pediatric cancers with NTRK fusionsEmily R Blauel, Theodore W Laetsch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2021
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerTheodore W Laetsch, David S Hong
Pediatric Blood & Cancer|April 26, 2017
Targeting NTRK fusions for the treatment of congenital mesoblastic nephromaTheodore W Laetsch, Ramamoorthy Nagasubramanian, Michela Casanova
Cancer Genetics|June 21, 2022
EditorialMarilyn M Li, Alexander Drilon, Theodore W Laetsch
Paediatric Drugs|November 22, 2019
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic LeukemiaHolly L Pacenta, Theodore W Laetsch, Samuel John
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Clinical Advances in Hematology & Oncology : H&O|May 13, 2024
Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinibTheodore W Laetsch
The Lancet. Haematology|October 22, 2020
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?Theodore W Laetsch
The Lancet. Oncology|January 8, 2020
Immunoglobulin replacement and quality of life after CAR T-cell therapy - Authors' replyTheodore W Laetsch, Andrew C Harris
Expert Review of Anticancer Therapy|September 13, 2022
Targeting the DNA damage response in pediatric malignanciesJenna M Gedminas, Theodore W Laetsch
Expert Review of Anticancer Therapy|October 24, 2018
Larotrectinib for the treatment of TRK fusion solid tumorsTheodore W Laetsch, Douglas S Hawkins
Cancer Genetics|February 2, 2022
The promise of TRK inhibitors in pediatric cancers with NTRK fusionsEmily R Blauel, Theodore W Laetsch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2021
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerTheodore W Laetsch, David S Hong
Pediatric Blood & Cancer|April 26, 2017
Targeting NTRK fusions for the treatment of congenital mesoblastic nephromaTheodore W Laetsch, Ramamoorthy Nagasubramanian, Michela Casanova
Cancer Genetics|June 21, 2022
EditorialMarilyn M Li, Alexander Drilon, Theodore W Laetsch
Paediatric Drugs|November 22, 2019
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic LeukemiaHolly L Pacenta, Theodore W Laetsch, Samuel John
Pageof 14